NCT04794218 - A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath | Biotech Hunter

Enrollment

114

Participants

Timeline

Start Date

June 23, 2021

Primary Completion Date

December 19, 2023

Study Completion Date

March 31, 2024

Conditions

Lassa FeverLassa Virus Infection

Interventions

DRUG

rVSV∆G-LASV-GPC

2 × 10\^4 pfu delivered intramuscularly

DRUG

rVSV∆G-LASV-GPC

2 × 10\^5 pfu delivered intramuscularly

DRUG

rVSV∆G-LASV-GPC

2 × 10\^6 pfu delivered intramuscularly

DRUG

rVSV∆G-LASV-GPC

2 × 10\^7 pfu delivered intramuscularly

OTHER

Placebo/Diluent

N/A delivered intramuscularly

Trial Locations (4)

George Washington University, Washington D.C.

East-West Medical Research Institute, Honolulu

Brigham and Women's Hospital, Brookline

Redemption Hospital, New Kru Town